Project Grant W81XWH1810606

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research investigating the mechanisms underlying beneficial effects of influenza A virus co-infection on viral replication and propagation. Awarded to Emory University in the amount of $246,562, the project runs from June 27, 2025, through January 31, 2028. The research focuses on understanding positive...

Federal Grant Award Summary: IN-005 Inhaled Muco-Trapping Monoclonal Antibody Therapy Inhalon Biopharma, Inc. received a $1,013,003 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2028. The grant supports the development and IND (Investigational New Drug)-enabling studies for IN-005, an inhaled monoclonal antibody (mAb) therapeutic...

Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $1.67 million Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 25, 2025, with an ultimate completion date of July 31, 2030. This Phase 1 study focuses on developing and evaluating a novel messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine for SARS-CoV-2 that incorporates two innovative technologies:...

Federal Project Grant Award Summary Inhalon Biopharma, Inc. received a $1,013,468 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 1, 2025, with completion scheduled for July 31, 2028. The company is developing IN-003PI, a passive immunization therapeutic comprised of two neutralizing monoclonal antibodies (mAbs) targeting human metapneumovirus (hMPV) fusion...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,074,701 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University. The project, titled "Drivers of Influenza A Virus Transmission in Humans," aims to address gaps in understanding the biological and physical processes underlying the transmission of influenza A virus in humans. The key objectives are to: 1) Define the dynamics of viral load, immunological...

Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Georgia State University Research Foundation Inc. a $6.68 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, with a completion date of July 31, 2029. This award supports the development of next-generation antiviral therapeutics targeting seasonal and pandemic influenza viruses. The primary deliverables include advancing prodrug conjugates...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Kentucky Research Foundation a $454,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 15, 2025, with a completion date of July 31, 2027. The research initiative focuses on developing an adjuvanted intranasal influenza vaccine formulation incorporating R-DOTAP (an enantiomer-specific cationic lipid) designed to generate...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $661,313 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, for a research project titled "Elicitation of Pan-Influenza A Antibodies via Simple B Cell Development Pathways." Led by Principal Investigator Dr. Daniel Lingwood with Co-Investigators Dr. Batista and Dr. Andrew Ward, this R01 project will...

The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...